TW201717938A - 治療或預防急性腦部或神經損傷的方法 - Google Patents
治療或預防急性腦部或神經損傷的方法 Download PDFInfo
- Publication number
- TW201717938A TW201717938A TW105125790A TW105125790A TW201717938A TW 201717938 A TW201717938 A TW 201717938A TW 105125790 A TW105125790 A TW 105125790A TW 105125790 A TW105125790 A TW 105125790A TW 201717938 A TW201717938 A TW 201717938A
- Authority
- TW
- Taiwan
- Prior art keywords
- acute brain
- acute
- injury
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562205431P | 2015-08-14 | 2015-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201717938A true TW201717938A (zh) | 2017-06-01 |
Family
ID=56801810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW105125790A TW201717938A (zh) | 2015-08-14 | 2016-08-12 | 治療或預防急性腦部或神經損傷的方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12042482B2 (enExample) |
| EP (1) | EP3334425B1 (enExample) |
| JP (1) | JP6862446B2 (enExample) |
| CN (1) | CN107921024B (enExample) |
| AU (1) | AU2016309815B2 (enExample) |
| CA (1) | CA2994974C (enExample) |
| DK (1) | DK3334425T3 (enExample) |
| TW (1) | TW201717938A (enExample) |
| WO (1) | WO2017030968A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201717938A (zh) | 2015-08-14 | 2017-06-01 | Ｑｒ製藥股份有限公司 | 治療或預防急性腦部或神經損傷的方法 |
| EP3654957A4 (en) | 2017-05-24 | 2021-06-23 | Annovis Bio, Inc. | PREVENTION OR TREATMENT OF DISEASE CONDITIONS DUE TO METAL DIS-HOMEOSTASIS BY ADMINISTERING POSIPHES TO HEALTHY OR SICK PEOPLE |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171750A (en) | 1991-09-26 | 1992-12-15 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted phenserines as specific inhibitors of acetylcholinesterase |
| US5409948A (en) | 1992-11-23 | 1995-04-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method for treating cognitive disorders with phenserine |
| WO1999002154A1 (en) | 1997-07-09 | 1999-01-21 | Axonyx | Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias |
| DE60124730T2 (de) | 2000-03-03 | 2007-10-04 | Eisai R&D Management Co., Ltd. | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| WO2002048150A2 (en) | 2000-11-02 | 2002-06-20 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof |
| US6495700B1 (en) | 2002-01-09 | 2002-12-17 | Axonyx, Inc. | Process for producing phenserine and its analog |
| US20040024043A1 (en) | 2002-03-22 | 2004-02-05 | Nigel Greig | Method for treating cognitive disorders |
| WO2004034963A2 (en) | 2002-05-17 | 2004-04-29 | Eisai Co., Ltd. | Methods and compositions using cholinesterase inhibitors |
| EP1617844A4 (en) | 2003-04-03 | 2009-07-22 | Prana Biotechnology Ltd | TREATMENT OF NEUROLOGICAL DISEASES |
| US20050013869A1 (en) | 2003-07-18 | 2005-01-20 | Chaw Cheng Shu | Sustained release formulation for carbamates and a method therefor |
| US20050182044A1 (en) | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
| WO2005091987A2 (en) | 2004-03-19 | 2005-10-06 | Axonyx, Inc. | Method of treating down syndrome |
| WO2005089746A1 (en) | 2004-03-19 | 2005-09-29 | Axonyx, Inc. | Dosage titration for treatment of cognitive disorders |
| EP1604686A1 (en) | 2004-06-08 | 2005-12-14 | Axonyx, Inc. | Use of phenserine and a HMG CoA reductase inhibitor for delaying Alzheimer's disease progression |
| WO2008134618A2 (en) | 2007-04-27 | 2008-11-06 | The General Hospital Corporation | Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders |
| WO2010117727A2 (en) | 2009-03-30 | 2010-10-14 | The General Hospital Corporation | Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions |
| US20120225922A1 (en) | 2011-03-04 | 2012-09-06 | Qr Pharma | Effective Amounts of (3aR)-1,3a,8-Trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo [2,3-b]indol-5-yl Phenylcarbamate and Methods of Treating or Preventing Neurodegeneration |
| TW201717938A (zh) | 2015-08-14 | 2017-06-01 | Ｑｒ製藥股份有限公司 | 治療或預防急性腦部或神經損傷的方法 |
-
2016
- 2016-08-12 TW TW105125790A patent/TW201717938A/zh unknown
- 2016-08-12 DK DK16757422.7T patent/DK3334425T3/da active
- 2016-08-12 EP EP16757422.7A patent/EP3334425B1/en active Active
- 2016-08-12 CN CN201680046586.2A patent/CN107921024B/zh active Active
- 2016-08-12 WO PCT/US2016/046794 patent/WO2017030968A1/en not_active Ceased
- 2016-08-12 CA CA2994974A patent/CA2994974C/en active Active
- 2016-08-12 AU AU2016309815A patent/AU2016309815B2/en active Active
- 2016-08-12 US US15/751,337 patent/US12042482B2/en active Active
- 2016-08-12 JP JP2018527851A patent/JP6862446B2/ja active Active
-
2024
- 2024-06-18 US US18/746,815 patent/US20250000846A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2994974A1 (en) | 2017-02-23 |
| CN107921024B (zh) | 2021-09-10 |
| JP6862446B2 (ja) | 2021-04-21 |
| EP3334425B1 (en) | 2020-12-16 |
| CA2994974C (en) | 2024-04-09 |
| JP2018523709A (ja) | 2018-08-23 |
| US20250000846A1 (en) | 2025-01-02 |
| DK3334425T3 (da) | 2021-02-22 |
| US20180228771A1 (en) | 2018-08-16 |
| CN107921024A (zh) | 2018-04-17 |
| EP3334425A1 (en) | 2018-06-20 |
| HK1253901A1 (en) | 2019-07-05 |
| US12042482B2 (en) | 2024-07-23 |
| WO2017030968A1 (en) | 2017-02-23 |
| AU2016309815B2 (en) | 2022-04-07 |
| AU2016309815A1 (en) | 2018-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Puerta et al. | Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer’s disease | |
| Cheung et al. | Neuroprotection in glaucoma: drug‐based approaches | |
| Saatman et al. | Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat. | |
| US20250000846A1 (en) | Methods of treatment or prevention of acute brain or nerve injuries | |
| KR102412997B1 (ko) | 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 | |
| CN110248650A (zh) | 用于增强突触发生和神经突发生的方法 | |
| KR20150095681A (ko) | 보르티옥세틴 및 도네페질을 포함하는 조성물 | |
| EP2882495A1 (en) | Laquinimod for treatment of cannabinoid receptor type 1 (cb1) mediated disorders | |
| KR102623819B1 (ko) | 시누클레인병변을 치료하기 위한 조성물 및 방법 | |
| TW201900163A (zh) | 用於治療共核蛋白病的唑尼沙胺(zonisamide)與普拉克素(pramipexole)之醫藥組合及相關方法 | |
| TW201841630A (zh) | 醫藥組合及其用於治療突觸核蛋白病症之用途 | |
| US20230212225A1 (en) | Peptide compostions and methods for treating tauopathies | |
| HK1253901B (en) | Methods of treatment or prevention of acute brain or nerve injuries | |
| WO2018116293A1 (en) | Low dose drug combinations for use in preventing and treating neuronal damage | |
| US11826340B1 (en) | Method for treateing or preventing ischemic optic neuropathy | |
| Riess et al. | Therapeutic strategies for Parkinson's disease based on data derived from genetic research | |
| KR102153648B1 (ko) | 산화적 스트레스로부터 성상세포를 보호하는 조성물 | |
| Yan et al. | The NMDAR/TRPM4 death complex is a major promoter of disease progression in the 5xFAD mouse model of Alzheimer’s | |
| JP2004531480A (ja) | 神経変性疾患の処置のためのトリペプチド誘導体 | |
| HK1250489B (en) | Substances containing gold clusters and preparation method and use thereof | |
| Irache | Effect of the oral administration of nanoencapsulated quercetin on a mouse model of Alzheimer's disease | |
| Arshaduddin et al. | Ahmad Al Mutairy1, Khalaf Al Moutaery2, Abdulrahman Al Asmari2 | |
| HK40019782A (en) | Agent for preventing or treating brain atrophy | |
| Men et al. | Edaravone Dexborneol Attenuates Neuroinflammation by Regulating CXCL13/CXCR5/NF-κB Pathway in MCAO Rats |